November 30, 2005Expert Opinion on Pharmacotherapy
Levosimendan for the treatment of acute heart failure syndromes
Why the study?
Does levosimendan improve clinical outcomes and hemodynamics compared to dobutamine or placebo in patients with acute heart failure syndromes?
Population
Patients with acute and advanced chronic heart failure, including decompensated or postmyocardial infarction…
Comparison
Levosimendan vs Dobutamine or placebo
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support levosimendan in acute HF; leaves open need for confirmatory RCTs.
Structured PICO
Does levosimendan improve clinical outcomes and hemodynamics compared to dobutamine or placebo in patients with acute heart failure syndromes?
P
Population
Patients with acute and advanced chronic heart failure, including decompensated or postmyocardial infarction heart failure
I
Intervention
Levosimendan
C
Comparator
Dobutamine or placebo
O
Outcome
Clinical outcomes and hemodynamic parameters (cardiac output, systemic vascular resistance, pulmonary capillary wedge pressure)
Levosimendan represents an effective and safe calcium-sensitizing inotropic option for the treatment of decompensated heart failure.
Cite This Study
Parissis et al. (2005) studied this question.